@article{rossano_use_2017,
	title = {Use of sirolimus in pediatric heart transplant patients: {A} multi-institutional study from the {Pediatric} {Heart} {Transplant} {Study} {Group}.},
	volume = {36},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/28029575},
	doi = {10.1016/j.healun.2016.09.009},
	abstract = {BACKGROUND: Proliferation signal inhibitors, such as sirolimus, are increasingly used in solid-organ transplantation. However, limited data exist on sirolimus-treated pediatric patients. We aimed to describe sirolimus use in pediatric heart transplant patients and test the hypothesis that sirolimus use is associated with improved outcomes. METHODS: A retrospective review and propensity-matched analysis of the Pediatric Heart Transplant Study database was performed on patients undergoing primary heart transplantation from 2004 to 2013 with at least 1 year of follow-up comparing patients treated vs not treated with sirolimus at 1 year after transplant. The primary outcome of interest was patient survival, with secondary outcomes including cardiac allograft vasculopathy, rejection, malignancy, and renal insufficiency. RESULTS: Between 2004 and 2013, 2,531 patients underwent transplantation. At least 1 year of follow-up was available for 2,080 patients, of whom 144 (7\%) were on sirolimus at 1 year post-transplant. Sirolimus-treated and non-treated patients had similar survival in the overall cohorts and in the propensity-matched analysis. The secondary outcomes measures were also similar, including a composite end point of all outcome measures. There was a trend toward increased time to cardiac allograft vasculopathy (p = 0.09) and decreased time to infection (p = 0.05) among sirolimus-treated patients in the overall cohort (p = 0.19) but not in the propensity-matched cohort (p = 0.17). CONCLUSIONS: Sirolimus was used in less than 10\% of patients at 1 year post-transplant. Overall outcomes of sirolimus treated and non-treated patients were similar with respect to survival and major transplant adverse events. Further study of sirolimus in pediatric heart transplant patients is needed.},
	language = {eng},
	number = {4},
	journal = {J Heart Lung Transplant},
	author = {Rossano, JW and Jefferies, JL and Pahl, E and Naftel, DC and Pruitt, E and Lupton, K and Dreyer, WJ and Chinnock, R and Boyle, G and Mahle, WT and Investigators, Pediatric Heart Transplant Study},
	month = apr,
	year = {2017},
	keywords = {Treatment Outcome},
	pages = {427--433}
}

{"_id":"P43YpdtYELrFBAdQP","bibbaseid":"rossano-jefferies-pahl-naftel-pruitt-lupton-dreyer-chinnock-etal-useofsirolimusinpediatrichearttransplantpatientsamultiinstitutionalstudyfromthepediatrichearttransplantstudygroup-2017","downloads":0,"creationDate":"2019-02-06T19:35:20.835Z","title":"Use of sirolimus in pediatric heart transplant patients: A multi-institutional study from the Pediatric Heart Transplant Study Group.","author_short":["Rossano, J.","Jefferies, J.","Pahl, E","Naftel, D.","Pruitt, E","Lupton, K","Dreyer, W.","Chinnock, R","Boyle, G","Mahle, W.","Investigators, P. H. T. S."],"year":2017,"bibtype":"article","biburl":"https://api.zotero.org/users/5494130/collections/MMMC8Y8W/items?key=gVbN80CrzLcU2vBNYPQc5lZY&format=bibtex&limit=100","bibdata":{"bibtype":"article","type":"article","title":"Use of sirolimus in pediatric heart transplant patients: A multi-institutional study from the Pediatric Heart Transplant Study Group.","volume":"36","url":"https://www.ncbi.nlm.nih.gov/pubmed/28029575","doi":"10.1016/j.healun.2016.09.009","abstract":"BACKGROUND: Proliferation signal inhibitors, such as sirolimus, are increasingly used in solid-organ transplantation. However, limited data exist on sirolimus-treated pediatric patients. We aimed to describe sirolimus use in pediatric heart transplant patients and test the hypothesis that sirolimus use is associated with improved outcomes. METHODS: A retrospective review and propensity-matched analysis of the Pediatric Heart Transplant Study database was performed on patients undergoing primary heart transplantation from 2004 to 2013 with at least 1 year of follow-up comparing patients treated vs not treated with sirolimus at 1 year after transplant. The primary outcome of interest was patient survival, with secondary outcomes including cardiac allograft vasculopathy, rejection, malignancy, and renal insufficiency. RESULTS: Between 2004 and 2013, 2,531 patients underwent transplantation. At least 1 year of follow-up was available for 2,080 patients, of whom 144 (7%) were on sirolimus at 1 year post-transplant. Sirolimus-treated and non-treated patients had similar survival in the overall cohorts and in the propensity-matched analysis. The secondary outcomes measures were also similar, including a composite end point of all outcome measures. There was a trend toward increased time to cardiac allograft vasculopathy (p = 0.09) and decreased time to infection (p = 0.05) among sirolimus-treated patients in the overall cohort (p = 0.19) but not in the propensity-matched cohort (p = 0.17). CONCLUSIONS: Sirolimus was used in less than 10% of patients at 1 year post-transplant. Overall outcomes of sirolimus treated and non-treated patients were similar with respect to survival and major transplant adverse events. Further study of sirolimus in pediatric heart transplant patients is needed.","language":"eng","number":"4","journal":"J Heart Lung Transplant","author":[{"propositions":[],"lastnames":["Rossano"],"firstnames":["JW"],"suffixes":[]},{"propositions":[],"lastnames":["Jefferies"],"firstnames":["JL"],"suffixes":[]},{"propositions":[],"lastnames":["Pahl"],"firstnames":["E"],"suffixes":[]},{"propositions":[],"lastnames":["Naftel"],"firstnames":["DC"],"suffixes":[]},{"propositions":[],"lastnames":["Pruitt"],"firstnames":["E"],"suffixes":[]},{"propositions":[],"lastnames":["Lupton"],"firstnames":["K"],"suffixes":[]},{"propositions":[],"lastnames":["Dreyer"],"firstnames":["WJ"],"suffixes":[]},{"propositions":[],"lastnames":["Chinnock"],"firstnames":["R"],"suffixes":[]},{"propositions":[],"lastnames":["Boyle"],"firstnames":["G"],"suffixes":[]},{"propositions":[],"lastnames":["Mahle"],"firstnames":["WT"],"suffixes":[]},{"propositions":[],"lastnames":["Investigators"],"firstnames":["Pediatric","Heart","Transplant","Study"],"suffixes":[]}],"month":"April","year":"2017","keywords":"Treatment Outcome","pages":"427–433","bibtex":"@article{rossano_use_2017,\n\ttitle = {Use of sirolimus in pediatric heart transplant patients: {A} multi-institutional study from the {Pediatric} {Heart} {Transplant} {Study} {Group}.},\n\tvolume = {36},\n\turl = {https://www.ncbi.nlm.nih.gov/pubmed/28029575},\n\tdoi = {10.1016/j.healun.2016.09.009},\n\tabstract = {BACKGROUND: Proliferation signal inhibitors, such as sirolimus, are increasingly used in solid-organ transplantation. However, limited data exist on sirolimus-treated pediatric patients. We aimed to describe sirolimus use in pediatric heart transplant patients and test the hypothesis that sirolimus use is associated with improved outcomes. METHODS: A retrospective review and propensity-matched analysis of the Pediatric Heart Transplant Study database was performed on patients undergoing primary heart transplantation from 2004 to 2013 with at least 1 year of follow-up comparing patients treated vs not treated with sirolimus at 1 year after transplant. The primary outcome of interest was patient survival, with secondary outcomes including cardiac allograft vasculopathy, rejection, malignancy, and renal insufficiency. RESULTS: Between 2004 and 2013, 2,531 patients underwent transplantation. At least 1 year of follow-up was available for 2,080 patients, of whom 144 (7\\%) were on sirolimus at 1 year post-transplant. Sirolimus-treated and non-treated patients had similar survival in the overall cohorts and in the propensity-matched analysis. The secondary outcomes measures were also similar, including a composite end point of all outcome measures. There was a trend toward increased time to cardiac allograft vasculopathy (p = 0.09) and decreased time to infection (p = 0.05) among sirolimus-treated patients in the overall cohort (p = 0.19) but not in the propensity-matched cohort (p = 0.17). CONCLUSIONS: Sirolimus was used in less than 10\\% of patients at 1 year post-transplant. Overall outcomes of sirolimus treated and non-treated patients were similar with respect to survival and major transplant adverse events. Further study of sirolimus in pediatric heart transplant patients is needed.},\n\tlanguage = {eng},\n\tnumber = {4},\n\tjournal = {J Heart Lung Transplant},\n\tauthor = {Rossano, JW and Jefferies, JL and Pahl, E and Naftel, DC and Pruitt, E and Lupton, K and Dreyer, WJ and Chinnock, R and Boyle, G and Mahle, WT and Investigators, Pediatric Heart Transplant Study},\n\tmonth = apr,\n\tyear = {2017},\n\tkeywords = {Treatment Outcome},\n\tpages = {427--433}\n}\n\n","author_short":["Rossano, J.","Jefferies, J.","Pahl, E","Naftel, D.","Pruitt, E","Lupton, K","Dreyer, W.","Chinnock, R","Boyle, G","Mahle, W.","Investigators, P. H. T. S."],"key":"rossano_use_2017","id":"rossano_use_2017","bibbaseid":"rossano-jefferies-pahl-naftel-pruitt-lupton-dreyer-chinnock-etal-useofsirolimusinpediatrichearttransplantpatientsamultiinstitutionalstudyfromthepediatrichearttransplantstudygroup-2017","role":"author","urls":{"Paper":"https://www.ncbi.nlm.nih.gov/pubmed/28029575"},"keyword":["Treatment Outcome"],"downloads":0,"html":""},"search_terms":["use","sirolimus","pediatric","heart","transplant","patients","multi","institutional","study","pediatric","heart","transplant","study","group","rossano","jefferies","pahl","naftel","pruitt","lupton","dreyer","chinnock","boyle","mahle","investigators"],"keywords":["treatment outcome"],"authorIDs":[],"dataSources":["GNcu7yQLspAdiCS2X"]}